Research goals: Metabolic & Weight Description Retatrutide (development code LY3437943) is a synthetic, once-weekly triple agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors that has been the subject of peer-reviewed phase 1 and phase 2 randomized controlled trials published in The New England Journal of Medicine , The Lancet , and Nature Medicine , including investigations of body weight, glycemic control, and hepatic steatosis in adult human participants
Please read all labels, warnings, and directions before use
d-glucose, d-mannitol, and lithium chloride were purchased from Wako Pure Chemical Industries, Ltd
New options like semaglutide are becoming more popular
10.1016/j.pneurobio.2011.06.003 Prog
Insurers may be less incentivized to adopt coverage because they could attract a "more expensive" set of patients than competitors who don't participate, he said